Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 27, 2020

View Archived Issues

Sotira successfully completes preclinical testing of KEPTIDE COVID

Phase II experience with transmission blocking vaccine Pfs230D1M-EPA/AS01

Two first-in-human adjuvanted malaria vaccines presented

ASGR1-TLR8: an immunoTAC for the potential treatment of chronic HBV

Genfleet Therapeutics describes new RIPK1 inhibitors

TYK Medicines divulges protein kinase inhibitors

Idorsia Pharmaceuticals synthesizes new PDK1 inhibitors

Chaser Therapeutics identifies new USP28 and USP25 inhibitors

Constellation Pharmaceuticals initiates phase III MANIFEST-2 study of CPI-0610

Initial successful data presented for RLF-100 in critical COVID-19 with severe comorbidity

Abmax Biopharmaceuticals TNF-alpha-targeting antibodies

Ionis licenses second NASH candidate to AstraZeneca

Merck initiates phase II study of MK-3655 in precirrhotic NASH

Aleta presents novel CAR T-engager proteins targeting metastatic and primary CNS malignancies

Promising phase II data for MDNA-55 delivered by CED in patients with recurrent GBM

New mutations don't appear to increase SARS-CoV-2 transmissibility

Novel model of SARS-CoV-2 infection in deer mice

Faron outlines expansion plans for Clevegen development

Golden Biotechnology reports phase IIa results with antroquinonol in relapsed AML

Phase IIb data presented for GMZ2 malaria vaccine in children

Evrenzo approved in Japan for CKD anemia in adults not on dialysis

Haoma completes first-in-human study of NaQuinate for osteoporosis

E.U. approval for Symkevi with Kalydeco for children with cystic fibrosis aged 6-11 years

Petrovax partners with Intellogic to study Longidaze for pulmonary fibrosis in COVID-19 patients

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...